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 Introduction 
 Trimethoprim, generally combined with sulfamethox-
azol (Sfx), is one of the most frequently prescribed antibi-
otics in nephrology. This combinations, also known as 
co-trimoxazole, is indicated for the preventive or curative 
treatment of urinary infections (in all populations) and 
of  Pneumocystis jirovecii infections (in HIV+ and trans-
planted patients)  [1–3] . Trimethoprim was fully described 
for the first time in 1962  [4] and has been available in Eu-
rope since 1968 in combination with Sfx. Co-trimoxazole 
is rapidly and efficiently absorbed after oral administra-
tion. Peak serum concentrations are observed in the first 
4 h  [2, 5] ; 66% of Sfx and 45% of trimethoprim are bound 
to protein  [2] , 10–30% of trimethoprim and 20% of Sfx 
are metabolized, and the metabolites are inactive  [6] . The 
parent compounds are excreted in the urine and bile. In 
individuals with normal renal function, the plasma half-
lives of trimethoprim and Sfx are 11 and 9 h, respectively 
 [7] . If the creatinine clearance is below 15–30 ml/min, it 
is recommended to decrease the total dose per 24 h by half 
 [2, 8] . In 1968, Hanley  [9] suspected a causal role of co-
trimoxazole in 4 cases of oliguria that occurred within 
the first 6 months after commercialization of co-trimox-
azole. However, the potential nephrotoxicity of trime-
thoprim and/or Sfx has been questioned  [10] . 
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 Abstract 
 Co-trimoxazole is a frequently prescribed antibiotic world-
wide. It is composed of both trimethoprim and sulfamethox-
azol (Sfx) and is used in the treatment and prophylaxis of 
urinary tract and  Pneumocystis jirovecii infections. The Sfx 
component appears to be nephrotoxic at high doses or dos-
es inappropriately adjusted for glomerular filtration rate 
(GFR). The trimethoprim component, even at recommended 
doses, inhibits tubular creatinine secretion, leading to a rap-
id but ultimately reversible increase in serum creatinine in-
dependent of any changes in GFR. This translates into a false-
ly low estimated GFR when creatinine-based equations are 
used. This review focuses on evidence of the differential ef-
fects of trimethoprim and Sfx on serum creatinine concen-
trations and GFR and their relevance to clinical practice, with 
particular attention to kidney transplantation. 
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 Are Trimethoprim and/or Sfx Nephrotoxic? The First 
Cases 
 The first article on this specific topic was published in 
1973 by Kalowski et al.  [11] ,  who retrospectively described 
16 cases of acute renal failure who had been treated with 
high-dose co-trimoxazole (800 or 1,600 mg Sfx and 80 
mg trimethoprim per day). Fourteen of these patients had 
preexisting chronic kidney disease (CKD), defined as se-
rum creatinine  1 1.5 mg/dl. Overall, serum creatinine in-
creased from 3.0  8 0.56 to 5.6  8 0.92 mg/dl and creati-
nine clearance decreased from 40 to 16 ml/min. In 3 pa-
tients, serum creatinine did not return to baseline after 
cessation of therapy. Renal biopsies were performed in 
2 patients and showed acute tubular necrosis  [11] . Sub-
sequently, others have reported cases of biopsy-proven 
tubulointerstitial nephrotoxicity, with high doses of
co-trimoxazole occurring mainly, but not exclusively, in 
patients with CKD  [12–20] . Since tubulointerstitial ne-
phritis has also been described with other sulfonamides 
in monotherapy  [11, 21] , Kalowski et al.  [11] hypothesized 
that co-trimoxazole nephrotoxicity was probably related 
to Sfx rather than to trimethoprim. Several authors have 
subsequently shown that renal safety seems to be excel-
lent if appropriate dose adjustments are made for im-
paired renal function  [22, 23] . In 1975, Tasker et al.  [22] 
 prospectively followed 20 CKD patients (mean serum 
creatinine: 4.47 mg/dl) with urinary or respiratory infec-
tion treated with co-trimoxazole. Three patients suffered 
from a nonreversible deterioration of their renal func-
tion, which was attributed to sepsis-related acute renal 
failure and acute tubular necrosis rather than to co-tri-
moxazole  [22, 24] . Although the authors state that the 
remaining 17 patients did not experience any significant 
change in serum creatinine  [22] , a review of the data pre-
sented reveals that 11 experienced a rise in serum creati-
nine of 0.2–0.8 mg/dl during the treatment  [13, 22] . This 
was, however, reversible in most patients, and serum cre-
atinine returned to baseline after therapy cessation. 
 Trimethoprim-Induced Serum Creatinine Elevation: 
The Evidence 
 In 1975, Berglund et al.  [25] published the first impor-
tant study illustrating the effect of trimethoprim on se-
rum creatinine. They described an increase in serum cre-
atinine in 21 sequential subjects (mean serum creatinine: 
0.85  8 0.18 mg/dl, range: 0.6 to 1.4 mg/dl) treated with 
co-trimoxazole at a dose of 1,600 mg Sfx and 160 mg tri-
methoprim per day for 12 days. During treatment, serum 
creatinine increased by an average of 0.22 mg/dl or 20%, 
with increases ranging from 0 to 0.4 mg/dl. Only 1 subject 
had a stable serum creatinine. The increase in serum cre-
atinine was higher in individuals with higher baseline se-
rum creatinine concentrations. All serum creatinine con-
centrations returned to baseline within 5 days after treat-
ment termination. Importantly, Berglund et al. excluded 
any type of analytical interferences. The addition of in-
creasing concentrations of co-trimoxazole to plasma did 
not modify serum creatinine measurement by the meth-
od of Jaffé. Although initially questioned  [26] , the ab-
sence of analytical interference was later confirmed by 3 
other authors  [27–29] . Berglund et al.  [25] also measured 
the creatinine clearance and glomerular filtration rate 
(GFR) by a reference method (iothalamate) in 4 healthy 
subjects before, during and after co-trimoxazole therapy. 
They described, for the first time ever, an increase in se-
rum creatinine with a concomitant fall in creatinine 
clearance and no significant change in GFR. This sug-
gested that the observed increase in creatinine was due to 
inhibition of tubular creatinine secretion rather than a 
result of a decline in GFR  [25] . In the same article, Berg-
l und et al. also showed that the effect of co-trimoxazole 
on creatinine begins as early as 2 h after intake and reach-
es a maximal peak within 4–6 h. Berglund et al. did not 
study the duration of the inhibition induced by co-tri-
moxazole, but, based on previous pharmacological stud-
ies, they suggested that this effect could last for at least
24 h  [1, 25, 30] . The final observation in the article by 
Bergl und et al. is interesting as well. After studying the 
effect of monotherapy with trimethoprim and Sfx in 2 
subjects, they concluded that the inhibition of tubular 
creatinine secretion was likely to be exclusively linked to 
trimethoprim rather than to Sfx. There are several limita-
tions to the study by Berglund et al. The sample size was 
small and no CKD patients were included. Moreover, cre-
atinine clearance was lower than GFR in 2 subjects, which 
is difficult to understand given tubular creatinine secre-
tion. Lastly, the inhibition of tubular creatinine secretion 
seems high (mean decrease in creatinine secretion of 
25%) in these healthy subjects  [31] . 
 In 1975, Caterson et al.  [24]  published another a priori 
interesting study. They studied 22 stable renal transplant 
recipients and measured GFR (inulin) before and after tri-
methoprim. Unlike Berglund et al.  [25] , they reported no 
significant changes in either GFR or creatinine clearance. 
However, these data are limited by a delay of 36 h between 
therapy cessation and GFR measurement. It was not until 
the eighties that a convincing confirmation of the hypoth-
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esis of Berglund et al.  [25] was published. Trollfors et al. 
 [32] measured GFR ( 51 Cr-EDTA clearance) in a heteroge-
neous group of 25 patients (GFR ranging from 13 to 160 
ml/min) before and during co-trimoxazole therapy (2.2–
7.1 mg/kg/day for 7–19 days). GFR remained stable in 21 
patients while serum creatinine increased from 1.32  8 
0.98 to 1.45  8 1.11 mg/dl and creatinine clearance de-
creased from 73  8 34 to 63  8 32 ml/min. The results of 
this study are somewhat difficult to interpret because of 
the heterogeneity in patients’ GFR and co-trimoxazole 
dosage. Moreover, all patients were infected and cannot 
be considered as ‘stable’. Lastly, the baseline GFR mea-
surement was performed after therapy had begun in 9 
subjects. Two of the CKD patients experienced a GFR de-
cline that was attributed to nephrotoxicity from high dos-
es of co-trimoxazole that were not adjusted for their de-
creased renal function. Two other patients also experi-
enced a decrease of their GFR that was attributed to sepsis 
and acute pyelonephritis  [32] . In 1981, Kainer and Rosen-
berg  [33] studied the effect of co-trimoxazole (30 mg/kg 
of Sfx and 6 mg/kg of trimethoprim) in 10 young healthy 
subjects. Serum creatinine, creatinine clearance and GFR 
( 51 Cr-EDTA) were measured before, on the 3rd and 7th 
day of therapy and 1 week after treatment cessation. Dur-
ing therapy, serum creatinine significantly increased by 
16.5% on the 3rd day and by 17.6% on the 7th day, while 
creatinine clearance decreased by 26.3 and 21.2% on the 
3rd and 7th day, respectively. All measurements returned 
to their original concentrations after the end of treatment. 
GFR remained unchanged throughout the course of ther-
apy  [33] . In 1985, Kastrup et al.  [27] studied trimethoprim 
alone. Fifteen healthy subjects were treated with 200 mg 
trimethoprim for 14 days. GFR ( 51 Cr-EDTA) and creati-
nine clearance were measured before and after therapy in 
6 subjects. Serum creatinine increased in all subjects. In 
the 6 patients in whom GFR was measured, serum creati-
nine increased by 23%, creatinine clearance decreased by 
22% and GFR was unchanged  [27] . In 1989, Berg et al.  [28] 
 examined the effects of co-trimoxazole therapy in renal 
transplant recipients. At that time, several authors had 
suggested that concomitant therapy with co-trimoxazole 
and cyclosporine could potentiate nephrotoxicity. This 
was based on retrospective data obtained from transplant 
recipients suffering from urinary or  P. jirovecii  infections 
and who were thus prone to sepsis-associated acute tubu-
lar necrosis  [18, 34–36] . Berg et al. included 16 stable, non-
infected renal transplant recipients. Eight were treated 
with cyclosporine. Their serum creatinine was below 2.04 
mg/dl and their mean GFR ( 99 Tc-DTPA) was 56 ml/min. 
The other 8 patients were treated with azathioprine and 
had serum creatinine concentrations below 1.81 mg/dl 
and mean GFRs of 74 ml/min. Trimethoprim was pre-
scribed at 320 mg for 7 days. Creatinine, creatinine clear-
ance and GFR were measured before and after therapy. A 
similar increase in serum creatinine concentration was 
observed in both groups (+28% in the cyclosporine group 
and +29% in the azathioprine group). A decrease in cre-
atinine clearance in both groups was also seen although 
this was more impressive in the cyclosporine group (24 vs. 
9%). Once again, GFR remained unchanged in all pa-
tients. Serum creatinine returned to baseline concentra-
tions 1 week after treatment cessation in all patients  [28] . 
In 1992, Maki et al.  [29]  also studied cyclosporine-treated 
renal transplant recipients. Using a cross-over design, 17 
stable, noninfected transplant recipients were alternately 
treated with prophylactic doses of co-trimoxazole (800 
mg Sfx and 160 mg trimethoprim) and placebo. GFR was 
identical in the two groups and remained unchanged 
throughout the study. During both treatment periods, the 
co-trimoxazole group had a higher mean serum creati-
nine and a lower mean creatinine clearance than the pla-
cebo group. Thus, in both of the above studies, no spe-
cific deleterious renal effects were observed with the com-
bination of cyclosporine and co-trimoxazole. Together, 
the above trials summarized in  table  1 support the hy-
pothesis originally proposed by Berglund et al.  [25] that 
trimethoprim inhibits tubular creatinine secretion  [25, 
27–29, 32, 33] . Trimethoprim is a cationic drug and its ef-
fect on tubular creatinine secretion is similar to that of 
cimetidine  [37] . Both act as inhibitors of organic cation 
transport via which creatinine is secreted in the distal tu-
bule  [28, 38–40] . This has been well documented in both 
cell cultures and animal studies  [38] . From a theoretical 
point of view, creatinine clearance measured in patients 
treated with trimethoprim would be a better estimator of 
GFR than creatinine clearance in patients not on trime-
thoprim. This has been documented with cimetidine, an-
other inhibitor of creatinine  [41] . 
 The magnitude of tubular creatinine secretion inhibi-
tion induced by trimethoprim has been explored by a 
number of groups  [30, 42–46] . Dijkmans et al.  [42]  found 
a 15–20% increase in serum creatinine in renal transplant 
recipients with urinary tract infections. Furthermore, the 
elevation was more pronounced in those with higher ini-
tial creatinine concentrations and the degree of elevation 
correlated with plasma trimethoprim concentrations 
(but not with Sfx concentrations). Roy et al.  [45]  treated 
10 healthy subjects with co-trimoxazole (1,600 mg Sfx 
and 160 mg trimethoprim) for 1 week followed by Sfx 
alone for 1 week after a 1-week washout period. Creati-
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nine increased by 13% only after co-trimoxazole, further 
confirming that inhibition of tubular creatinine secre-
tion is unique to trimethoprim. Sandberg and Trollfors 
 [46]  documented a 23% increase in serum creatinine in 
14 non-CKD patients with uncomplicated acute cystitis 
treated with trimethoprim (320 mg/day for 7 days). Myre 
et al.  [43] studied 10 noninfected healthy subjects and 9 
stable noninfected CKD patients (mean serum creati-
nine: 3.66  8 0.24 mg/dl) treated with trimethoprim (200 
mg) for 10 days. Serum creatinine reversibly increased by 
14.8% in the healthy subjects as compared to 34.6% in the 
CKD patients. Odutola et al.  [47]  showed a decrease in 
mean serum creatinine from 1.82  8 0.66 to 1.63  8 0.59 
mg/dl in 100 renal transplant recipients after cessation of 
co-trimoxazole therapy (800 mg Sfx and 80 mg trimeth-
oprim). The higher the initial creatinine concentration, 
the greater the proportional decrease. Naderer et al.  [44] 
 compared the differential effect of two different dosages 
of trimethoprim on serum creatinine in 20 healthy sub-
jects. With the classical antibacterial dosage (10 mg/kg/
day), serum creatinine increased by 26% (0.2  8 0.13 mg/
dl) as compared to 31% (0.28  8 0.18 mg/dl) with the 
higher dosage recommended for  P. jirovecii  infections (20 
mg/kg/day). These differences did not reach statistical 
significance, however.
 In all studies, serum creatinine reverted to baseline 
after cessation of therapy. However, the effect can last as 
a function of the drug half-life, which ranges from 11 to 
17 h)  [1, 2, 25, 30] depending on the GFR. In CKD pa-
tients, the drug half-life may be doubled or tripled  [1, 48] .
 Trimethoprim-Induced Serum Creatinine Elevation: 
Conclusions 
 Trimethoprim induces a reversible and rapid (2–6 h 
after intake)  [25, 30] increase in serum creatinine and a 
decrease in creatinine clearance. These occur indepen-
dently of changes in GFR and are mediated through in-
hibition of tubular creatinine secretion  [27–29, 32, 33, 49, 
50] . In healthy subjects, the increase in serum creatinine 
ranges between 13%  [33, 43, 46] and 23%  [25, 27, 32, 45] . 
The observed variation is likely due to differing dosages 
although this has not been definitely proven  [44] . The 
lowest dose of trimethoprim studied to date is 160 mg/
day and it is not known whether lower doses have the 
same effect on serum creatinine concentration  [29] . In 
patients with CKD, the increase in serum creatinine con-
centration is more pronounced than in healthy subjects 
and has been described to be higher than 35%  [25, 28, 42, 
43] , which is not unexpected given the known increase
in creatinine secretion as GFR declines. Studies to date 
reveal that trimethoprim possesses minimal if any true 
nephrotoxicity. To the best of our knowledge, no convinc-
ing cases of acute renal failure have been described with 
this drug in monotherapy at a prophylactic dosage. A sin-
gle patient treated with trimethoprim who developed 
acute kidney injury has been reported, but this is con-
founded by the concurrent use of a nonsteroidal anti-in-
flammatory drug  [51] . It is clear that the combination of 
trimethoprim and Sfx can induce acute renal failure, es-
pecially if the dosage is not appropriately adjusted to renal 
Table 1. T rials having studied the trimethoprim effect on serum creatinine using a reference method for GFR measurement




Berglund et al. [25] 21 infected patients




Trollfors et al. [32] 25 infected patients
Ctx (2.2–6.5 mg/kg/day)
1.3280.98 0.13 mg/dl (+10%)
Kainer and Rosenberg [33] 10 healthy subjects
Ctx (30 mg/kg/day Sfx + 6 mg/kg/day Tmp)
normal range +17%
Kastrup et al. [27] 15 healthy subjects
Tmp (200 mg/day)
normal range +23%
Berg et al. [28] 16 stable renal transplant recipients
Tmp (2! 160 mg)
<2.04 +28%
C onversion factors: serum creatinine in milligrams per deciliter to micromoles per liter: !88.4. Tmp = Trimethoprim; Ctx =
co-trimoxazole. 
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function  [2, 3] . However, it is likely that it is Sfx that is 
responsible for the vast majority of cases of ‘true’ acute 
renal failure occurring with co-trimoxazole therapy  [9, 
11–13, 32] .
 Trimethoprim, Renal Transplantation and GFR 
Estimation 
 The recent Kidney Disease: Improving Global Out-
comes (KDIGO) guidelines strongly recommend that all 
renal transplant recipients receive daily prophylaxis with 
co-trimoxazole for at least 6 months for both urinary 
tract and  P. jirovecii infection prevention  [52] . Either sin-
gle strength (80 mg as trimethoprim) or double strength 
(160 mg as trimethoprim) is acceptable. As discussed 
above, the effect of trimethoprim at 80 mg on serum cre-
atinine concentration is not known, while the higher 160 
mg dose does increase it by approximately 15%  [27, 43] . 
This will clearly influence GFR estimation using the 
Modification of Diet in Renal Disease (MDRD) study 
equation. 
 Because the relationship between serum creatinine 
and GFR is exponential, the effect of trimethoprim on 
estimated GFR will theoretically be higher in patients 
with low (or normal) creatinine levels. However, the ef-
fect of trimethoprim is especially relevant to higher cre-
atinine levels because it is linked to tubular creatinine 
secretion, which is GFR dependent. We will thus illus-
trate the effect of trimethoprim with the following ex-
ample. A 50-year-old man with a serum creatinine of 1.4 
mg/dl will have an estimated GFR of 54 ml/min/1.73 m 2 . 
A trimethoprim-induced 20% increase in serum creati-
nine to 1.68 mg/dl will reduce the estimated GFR to 43 
ml/min/1.73 m 2 . These changes in creatinine and esti-
mated GFR could be considered as clinically significant 
even though the GFR is actually unchanged. 
 Furthermore, the ability of serum creatinine and esti-
mated GFR based on serum creatinine to accurately de-
tect changes in true GFR in patients not on trimethoprim, 
which is far more important than their absolute levels, is 
less than optimal  [53, 54] . GFR estimation poses a par-
ticular challenge in kidney transplant recipients  [52, 55, 
56] . Trials evaluating the performance of the MDRD 
study equation and other creatinine-based equations 
show significant heterogeneity  [55, 56] . Several explana-
tions have been advanced to explain such discrepancies, 
such as differences in the reference method for GFR mea-
surement, in serum creatinine calibration and in GFR 
range of the study population  [56] . Another hypothesis 
involves the potential influence of trimethoprim on se-
rum creatinine, with differences between studies in the 
prevalence and dosage of co-trimoxazole  [56] . In two re-
cent studies with a similar distribution of GFR, isotope 
dilution mass spectrometry (IDMS) traceable serum cre-
atinine concentrations and the same reference method 
for GFR measurement ( 99 Tc-DTPA clearance) have ex-
amined the performance of the MDRD study equation 
 [57, 58] . In the first, the MDRD study equation underes-
timated GFR across the entire GFR range. In the second, 
the same equation systematically overestimated GFR. 
Twenty percent of the patients in the first study were 
treated with co-trimoxazole, while none was treated in 
the second. This could, at least in part, account for the 
discrepancies between the two trials. The potential role 
of trimethoprim in the performance of the creatinine-
based equations is illustrated by another trial published 
by White et al.  [59]  in 2007. In this sample of 192 renal 
transplant recipients, 19% were treated with co-trimoxa-
zole (160 mg trimethoprim 3 times per week). The accu-
racy of the MDRD study equation (defined as percentage 
of patients with an estimated GFR within 30% of mea-
sured GFR) was 80% in the entire cohort. In the subgroup 
of patients treated with trimethoprim, the accuracy was 
decreased to 62%.
 Conclusion 
 Co-trimoxazole is a recommended and widely used 
antibiotic for the prevention and treatment of  P. jirovecii 
pneumonia and urinary tract infections, especially in 
transplant recipients  [1–3, 52] . Sfx, and thus co-trimoxa-
zole, may cause an abrupt increase in serum creatinine 
due to tubulointerstitial toxicity in high or incorrectly ad-
justed doses. By inhibiting creatinine secretion, trime-
thoprim can also lead to an elevation in serum creatinine, 
but this is independent of any changes in GFR. This cre-
atinine ‘elevation’ impacts on GFR estimation and will 
lead to the erroneous perception of a more severely im-
paired kidney function than it actually is. 
 New GFR biomarkers could be of interest for subjects 
treated with trimethoprim. For example, plasma cys-
tatin C is freely filtrated through the glomerulus and is 
then reabsorbed by renal tubular cells where it is com-
pletely metabolized  [60] . Thus, trimethoprim should 
theoretically not influence plasma cystatin C concentra-
tions.
 The effect of trimethoprim on serum creatinine has 
rarely been studied in recent years. Therefore, more stud-
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ies are necessary to improve our understanding of the 
potential effect of low-dose (80 mg) trimethoprim on se-
rum creatinine levels. Collaborative trials are also wel-
come to study the potential effect of this drug on the per-
formance of the creatinine-based equations and to ex-
plain discrepancies observed between trials studying the 
performance of the MDRD study equation in renal trans-
plantation. The effect of trimethoprim on serum creati-
nine (and its consequences in terms of GFR estima-
tion) is an old topic, but it would deserve complementary 
studies. 
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 Trimethoprim (in the forms of trimethoprim-Sfx 
combinations – co-trimoxazole) is one of the most fre-
quently prescribed medications for acute urinary tract 
and for prophylaxis/treatment of opportunistic infec-
tions  (P. jirovecii) in immunocompromised patients. The 
article by Delanaye et al. on the influence of this agent on 
the estimation of renal function by creatinine-based 
equations is thus both important and timely. Such equa-
tions are commonly used to approximate renal function 
levels, GFR, for the diagnosis of chronic kidney disease, 
to evaluate the progression of renal disease (in patients 
with  native kidney disease and in renal allograft recipi-
ents), and for determining dosage of water-soluble thera-
peutic agents cleared by the kidney (mainly by glomeru-
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lar filtration). As shown by Delanaye et al., it is very clear 
that trimethoprim, even at customary dosages, competi-
tively reduces tubular creatinine secretion and thus leads 
to a reversible elevation of serum creatinine concentra-
tion, and in the steady state to no change in urinary cre-
atinine excretions. Thus  GFR estimated by conventional 
serum creatinine-based formulas (eGFR), such as the 
eGFR (MDRD) or the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation as well as the 
Cockcroft-Gault formula all will be systematically re-
duced (by about 20–25%). In addition, values from direct 
measurement of endogenous creatinine clearance will be 
similarly reduced. The value for GFR calculated from se-
rum cystatin C concentration or other noncreatinine 
markers of GFR will not be affected. The Sfx component 
of co-trimoxazole has no such effect on creatinine secre-
tion, but, under very uncommon circumstances, can 
cause direct or immune-mediated kidney injury.
 Recognition of these phenomena is crucially important 
in patients receiving co-trimoxazole, lest errors be made in 
the interpretation of estimates of renal function that can 
lead to misdiagnosis and misguided treatment. The con-
tribution of Delanaye et al. reminds us of this important 
topic, which has been neglected in the recent literature. 
